Case Report: Circulating Myeloid-Derived Suppressive-Like Cells and Exhausted Immune Cells in Non-Small Cell Lung Cancer Patients Treated With Three Immune Checkpoint Inhibitors

被引：2

作者：

Bronte, Giuseppe ^{[1
]}

Verlicchi, Alberto ^{[1
]}

De Matteis, Serena ^{[2
,3
]}

Rossi, Alice ^{[4
]}

Affatato, Alessandra ^{[5
]}

Sullo, Francesco Giulio ^{[1
]}

Gianni, Caterina ^{[1
]}

Canale, Matteo ^{[2
]}

Burgio, Marco Angelo ^{[1
]}

Delmonte, Angelo ^{[1
]}

Milella, Michele ^{[6
]}

Crino, Lucio ^{[1
]}

机构：

[1] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Dept Med Oncol, Meldola, Italy

[2] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Biosci Lab, Meldola, Italy

[3] Univ Bologna, Dept Expt Diagnost & Specialty Med, AlmaMater Studiorum, Bologna, Italy

[4] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Radiol Unit, Meldola, Italy

[5] IRCCS Ist Romagnolo Studio Tumori IRST Dino Amado, Unit Biostat & Clin Trials, Meldola, Italy

[6] Univ Verona, Sect Oncol, Dept Med, Verona, Italy

来源：

FRONTIERS IN IMMUNOLOGY | 2021年 / 12卷

关键词：

immune checkpoint inhibitor; CTLA-4; PD-1; LAG-3; myeloid-derived suppressor cells; T cell exhaustion; NIVOLUMAB;

D O I：

10.3389/fimmu.2021.672219

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

Immune checkpoint inhibition induced a great step forward in the treatment of non-small cell lung cancer patients. In cancer immune microenvironment many checkpoints were studied and their involvement could represent a mechanism of resistance to cancer immunotherapy. For this reason, the inhibition of multiple immune checkpoints is under development. However, myeloid-derived suppressor cells (MDSC) and exhausted immune cells could limit the efficacy of cancer immunotherapy. We analyzed the variation of circulating immune suppressive-like cell subsets and exhausted immune cells in three non-small cell lung cancer patients treated with the combination of anti-CTLA-4 plus anti-PD-1 plus anti-LAG-3 at T0 (baseline), T1 (after 2 months) and T2 (after 4 months). We also describe the clinical and radiological course of the disease during this treatment in all three patients. We observed both clinical differences and changes in the composition of immune suppressive-like cell subsets and exhausted immune cells between the patients receiving the same schedule of treatment with immune checkpoint inhibitors. The study on a wider patient population and experimental model design could help to clarify the kinetics of these cell subpopulations with the perspective to find new targets for treatment or new biomarkers for resistance to cancer immunotherapy.

引用

页数：6

共 11 条

[1] Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards [J].

Bronte, Vincenzo ;

Brandau, Sven ;

Chen, Shu-Hsia ;

Colombo, Mario P. ;

Frey, Alan B. ;

Greten, Tim F. ;

Mandruzzato, Susanna ;

Murray, Peter J. ;

Ochoa, Augusto ;

Ostrand-Rosenberg, Suzanne ;

Rodriguez, Paulo C. ;

Sica, Antonio ;

Umansky, Viktor ;

Vonderheide, Robert H. ;

Gabrilovich, Dmitry I. .

NATURE COMMUNICATIONS, 2016, 7

[2] CD8+ T Cells Specific for Tumor Antigens Can Be Rendered Dysfunctional by the Tumor Microenvironment through Upregulation of the Inhibitory Receptors BTLA and PD-1 [J].

Fourcade, Julien ;

Sun, Zhaojun ;

Pagliano, Ornella ;

Guillaume, Philippe ;

Luescher, Immanuel F. ;

Sander, Cindy ;

Kirkwood, John M. ;

Olive, Daniel ;

Kuchroo, Vijay ;

Zarour, Hassane M. .

CANCER RESEARCH, 2012, 72 (04) :887-896

[3] Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden [J].

Hellmann, M. D. ;

Ciuleanu, T. -E. ;

Pluzanski, A. ;

Lee, J. S. ;

Otterson, G. A. ;

Audigier-Valette, C. ;

Minenza, E. ;

Linardou, H. ;

Burgers, S. ;

Salman, P. ;

Borghaei, H. ;

Ramalingam, S. S. ;

Brahmer, J. ;

Reck, M. ;

O'Byrne, K. J. ;

Geese, W. J. ;

Green, G. ;

Chang, H. ;

Szustakowski, J. ;

Bhagavatheeswaran, P. ;

Healey, D. ;

Fu, Y. ;

Nathan, F. ;

Paz-Ares, L. .

NEW ENGLAND JOURNAL OF MEDICINE, 2018, 378 (22) :2093-2104

[4] Improved Survival with Ipilimumab in Patients with Metastatic Melanoma [J].

Hodi, F. Stephen ;

O'Day, Steven J. ;

McDermott, David F. ;

Weber, Robert W. ;

Sosman, Jeffrey A. ;

Haanen, John B. ;

Gonzalez, Rene ;

Robert, Caroline ;

Schadendorf, Dirk ;

Hassel, Jessica C. ;

Akerley, Wallace ;

van den Eertwegh, Alfons J. M. ;

Lutzky, Jose ;

Lorigan, Paul ;

Vaubel, Julia M. ;

Linette, Gerald P. ;

Hogg, David ;

Ottensmeier, Christian H. ;

Lebbe, Celeste ;

Peschel, Christian ;

Quirt, Ian ;

Clark, Joseph I. ;

Wolchok, Jedd D. ;

Weber, Jeffrey S. ;

Tian, Jason ;

Yellin, Michael J. ;

Nichol, Geoffrey M. ;

Hoos, Axel ;

Urba, Walter J. .

NEW ENGLAND JOURNAL OF MEDICINE, 2010, 363 (08) :711-723

[5] Population alterations of l-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14-/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer [J].

Liu, Chien-Ying ;

Wang, Yu-Min ;

Wang, Chih-Liang ;

Feng, Po-Hao ;

Ko, How-Wen ;

Liu, Yun-Hen ;

Wu, Yi-Cheng ;

Chu, Yen ;

Chung, Fu-Tsai ;

Kuo, Chih-Hsi ;

Lee, Kang-Yun ;

Lin, Shu-Min ;

Lin, Horng-Chyuan ;

Wang, Chun-Hua ;

Yu, Chih-Teng ;

Kuo, Han-Pin .

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2010, 136 (01) :35-45

[6] Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up [J].

Novello, S. ;

Barlesi, F. ;

Califano, R. ;

Cufer, T. ;

Ekman, S. ;

Levra, M. Giaj ;

Kerr, K. ;

Popat, S. ;

Reck, M. ;

Senan, S. ;

Simo, G. V. ;

Vansteenkiste, J. ;

Peters, S. .

ANNALS OF ONCOLOGY, 2016, 27 :v1-v27

[7] Association Between Response to Nivolumab Treatment and Peripheral Blood Lymphocyte Subsets in Patients With Non-small Cell Lung Cancer [J].

Ottonello, Selene ;

Genova, Carlo ;

Cossu, Irene ;

Fontana, Vincenzo ;

Rijavec, Erika ;

Rossi, Giovanni ;

Biello, Federica ;

Dal Bello, Maria Giovanna ;

Tagliamento, Marco ;

Alama, Angela ;

Coco, Simona ;

Boccardo, Simona ;

Vanni, Irene ;

Ferlazzo, Guido ;

Moretta, Lorenzo ;

Grossi, Francesco ;

Mingari, Maria Cristina ;

Carrega, Paolo ;

Pietra, Gabriella .

FRONTIERS IN IMMUNOLOGY, 2020, 11

[8] Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial [J].

Rittmeyer, Achim ;

Barlesi, Fabrice ;

Waterkamp, Daniel ;

Park, Keunchil ;

Ciardiello, Fortunato ;

von Pawel, Joachim ;

Gadgeel, Shirish M. ;

Hida, Toyoaki ;

Kowalski, Dariusz M. ;

Dols, Manuel Cobo ;

Cortinovis, Diego L. ;

Leach, Joseph ;

Polikoff, Jonathan ;

Barrios, Carlos ;

Kabbinavar, Fairooz ;

Frontera, Osvaldo Aren ;

De Marinis, Filippo ;

Turna, Hande ;

Lee, Jong-Seok ;

Ballinger, Marcus ;

Kowanetz, Marcin ;

He, Pei ;

Chen, Daniel S. ;

Sandler, Alan ;

Gandara, David R. .

LANCET, 2017, 389 (10066) :255-265

[9] Nivolumab in Previously Untreated Melanoma without BRAF Mutation [J].

Robert, Caroline ;

Long, Georgina V. ;

Brady, Benjamin ;

Dutriaux, Caroline ;

Maio, Michele ;

Mortier, Laurent ;

Hassel, Jessica C. ;

Rutkowski, Piotr ;

McNeil, Catriona ;

Kalinka-Warzocha, Ewa ;

Savage, Kerry J. ;

Hernberg, Micaela M. ;

Lebbe, Celeste ;

Charles, Julie ;

Mihalcioiu, Catalin ;

Chiarion-Sileni, Vanna ;

Mauch, Cornelia ;

Cognetti, Francesco ;

Arance, Ana ;

Schmidt, Henrik ;

Schadendorf, Dirk ;

Gogas, Helen ;

Lundgren-Eriksson, Lotta ;

Horak, Christine ;

Sharkey, Brian ;

Waxman, Ian M. ;

Atkinson, Victoria ;

Ascierto, Paolo A. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :320-330

[10] Plasticity of myeloid-derived suppressor cells in cancer [J].

Tcyganov, Evgenii ;

Mastio, Jerome ;

Chen, Eric ;

Gabrilovich, Dmitry I. .

CURRENT OPINION IN IMMUNOLOGY, 2018, 51 :76-82

← 1 2 →